Is the Answer Right in Front of Us? | GenomeWeb

MIT researcher Mark Bear says that biotechs hold the key to treating autism and some forms of mental retardation, with the drugs that are already on their lab shelves, says the Forbes Treatments blog's Robert Langreth. Bear's "radical" new theory suggest that a specific class of drug already developed by drug companies may help patients with an inherited disease, fragile X syndrome, which is thought to be a cause of autism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.